Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.50 Consensus Price Target from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $25.50.

Several equities analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Bank of America cut their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Finally, StockNews.com upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, March 7th.

Kura Oncology Stock Performance

KURA stock opened at $7.29 on Friday. Kura Oncology has a one year low of $6.79 and a one year high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $588.70 million, a price-to-earnings ratio of -3.09 and a beta of 0.85. The firm has a 50-day simple moving average of $7.84 and a two-hundred day simple moving average of $12.75.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, equities analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Kura Oncology by 7.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after buying an additional 9,050 shares in the last quarter. Woodline Partners LP lifted its stake in Kura Oncology by 20.6% in the 4th quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock valued at $1,504,000 after buying an additional 29,497 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in Kura Oncology in the 4th quarter valued at about $1,306,000. Squarepoint Ops LLC purchased a new position in Kura Oncology in the 4th quarter valued at about $799,000. Finally, Two Sigma Advisers LP lifted its stake in Kura Oncology by 147.1% in the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock valued at $2,110,000 after buying an additional 144,201 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.